L-carnitine,
does it really help with Improvement in sperm motility and the chance of natural conception in male infertility?
research showsL-carnitine or acetyl-L-carnitine shows a signal for improving total and progressive sperm motility in idiopathic male infertility, but trials are small, formulations and combinations vary, and results become unstable in sensitivity analyses. More importantly, increases in natural conception and live birth have not been demonstrated. Combining semen surrogates with actual pregnancy outcomes supports a C grade.
ads claimClaims of a dramatic increase in sperm count, guaranteed natural conception, replacement of in vitro fertilization, or treatment of male infertility convert a semen surrogate into an unproven live-birth effect. Idiopathic infertility, varicocele, endocrine disease, and obstruction are different conditions.
Useful facts when choosing a product
- Trials commonly used L-carnitine alone at 1-3 g/day or combined it with acetyl-L-carnitine for three to six months, which is not equivalent to a single 500 mg retail capsule.
- Products such as 500 mg capsules are available to Korean consumers as general supplements, but this is separate from authorization to treat male infertility; fumarate, tartrate, and acetyl forms should be distinguished.
- Gastrointestinal upset, diarrhea, and a characteristic body odor may occur; people with seizure history, kidney disease, or warfarin use should consult a clinician.
- Semen measurements vary with abstinence interval and laboratory conditions, so repeat testing and evaluation of both partners are needed.
What the research actually shows
The 2020 Khaw meta-analysis included eight randomized trials and reported improvements in total motility, progressive motility, and normal morphology, but not sperm concentration; five studies reporting clinical pregnancy showed no effect. The 2025 Michaelsen review synthesized fifty placebo-controlled trials lasting at least twelve weeks and found no supplement benefit for pregnancy or live birth. Carnitine showed a motility signal, but certainty was low or very low and total motility became nonsignificant in sensitivity analysis. The amended 2024 AUA-ASRM guideline advises counseling that the clinical utility of supplements is questionable.
Why this is classified as C (48)
Randomized trials and meta-analyses exist, but effects center on the sperm-motility surrogate, are vulnerable to sensitivity analysis and heterogeneity, and do not establish natural conception or live birth. The boundary rule supports C with 48 points.
Counterpoint. Adjunctive motility improvement may remain possible in some men with idiopathic asthenozoospermia. The central limitation is the inability to convert that possibility into an established pregnancy benefit.
Rejudgment record. New verdict — Limited positive sperm-motility surrogate signal, restricted to C by sensitivity-analysis instability, heterogeneity, and absent natural-conception and live-birth benefit
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Improvement in total and progressive sperm motility in idiopathic male infertility | C | Meta-analysis shows a positive signal, but certainty is low, heterogeneity is substantial, and sensitivity analysis is unstable. |
| Improvement in natural conception and live birth | C | Limited pregnancy data show no significant effect, and live-birth reporting is insufficient for a firm efficacy conclusion. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Khaw SC et al. 2020 | Systematic review and meta-analysis of randomized trials | 8 | Authors largely declared no conflicts | Sperm concentration, motility, morphology, and clinical pregnancy | Motility and morphology improved, but concentration and clinical pregnancy across five studies did not significantly improve. | Key |
| Michaelsen MP et al. 2025 | Systematic review and meta-analysis of placebo-controlled randomized trials | 50 | No funder role in this review | Pregnancy, live birth, and sperm parameters | Carnitine showed a motility signal, but total motility became nonsignificant in sensitivity analysis and pregnancy and live birth did not improve. | Key |
| de Ligny W et al. 2022 | Cochrane review of antioxidants | Cochrane | Live birth, clinical pregnancy, and adverse events | Pregnancy and live-birth evidence for antioxidants as a class was low or very low certainty and remained inconclusive. | Supportive |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-18).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-18 · Corrections: none
Cite this verdict
[Chamgap] L-carnitine x sperm motility and natural conception in male infertility — Evidence Grade C·48. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/mens/l-carnitine-male-infertility-motility-pregnancy/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.